WO2023115741A1 - 一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 - Google Patents
一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 Download PDFInfo
- Publication number
- WO2023115741A1 WO2023115741A1 PCT/CN2022/083659 CN2022083659W WO2023115741A1 WO 2023115741 A1 WO2023115741 A1 WO 2023115741A1 CN 2022083659 W CN2022083659 W CN 2022083659W WO 2023115741 A1 WO2023115741 A1 WO 2023115741A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- brassinolide
- sterol
- new crystal
- present
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000001647 brassinosteroids Chemical class 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000008635 plant growth Effects 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims description 114
- IXVMHGVQKLDRKH-VRESXRICSA-N Brassinolide Natural products O=C1OC[C@@H]2[C@@H]3[C@@](C)([C@H]([C@@H]([C@@H](O)[C@H](O)[C@H](C(C)C)C)C)CC3)CC[C@@H]2[C@]2(C)[C@@H]1C[C@H](O)[C@H](O)C2 IXVMHGVQKLDRKH-VRESXRICSA-N 0.000 claims description 41
- 229930182558 Sterol Natural products 0.000 claims description 38
- 235000003702 sterols Nutrition 0.000 claims description 38
- -1 brassinolide sterol Chemical class 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 150000001646 brassinolides Chemical class 0.000 claims description 18
- 239000000287 crude extract Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- 238000001228 spectrum Methods 0.000 claims description 13
- 240000002791 Brassica napus Species 0.000 claims description 9
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000002329 infrared spectrum Methods 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 2
- 241000219198 Brassica Species 0.000 claims 1
- 235000011331 Brassica Nutrition 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 abstract description 11
- 230000004071 biological effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000035784 germination Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000208125 Nicotiana Species 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- IXVMHGVQKLDRKH-KNBKMWSGSA-N brassinolide Chemical compound C1OC(=O)[C@H]2C[C@H](O)[C@H](O)C[C@]2(C)[C@H]2CC[C@]3(C)[C@@H]([C@H](C)[C@@H](O)[C@H](O)[C@@H](C)C(C)C)CC[C@H]3[C@@H]21 IXVMHGVQKLDRKH-KNBKMWSGSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N45/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P21/00—Plant growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention relates to the technical field of agrochemicals, in particular to a new brassinosteroid analogue, a new crystal form and a preparation method and application thereof.
- Natural brassinosterols are a general term for a class of lactone compounds and their sterol analogues. In addition to the identified BL, more than 60 different natural structures have been discovered, collectively called brassinosterols or brassinosterols ( Brassinosteroids, BRs). Our company has more than 20 years of research history on natural brassinolide sterols, and has developed a series of preparation processes for extracting natural brassinolide sterols from natural raw materials. Natural brassinoid sterol analogues (BR1-BR6) with different structures were isolated. On this basis, the applicant discovered a new structure of natural brassinosteroid sterol analogues through continuous in-depth development and continuous research.
- Compound polymorphism means that the active ingredient of a drug can form two or more molecular assembly modes during the crystallization process, and the appearance of polymorphism is the result of kinetic competition in the process of crystallization thermodynamics and molecular recognition.
- crystallization conditions such as: solvent composition, temperature, concentration, supersaturation, pH value, stirring speed, impurities, etc.
- the change of combination mode and force can make the crystal have different unit cell parameters and space groups, thus forming polymorphism.
- the present invention provides a new brassinolide sterol analogue, new crystal form and its preparation method and application.
- a product with significant biological activity can be obtained.
- the present invention realizes through following technical scheme:
- a brassinolide sterol analog the chemical formula of the brassinolide sterol analog is C 27 H 46 O 7 , and the chemical name is (20R,22R)-2 ⁇ ,3 ⁇ ,14 ⁇ -14,20,22,25- Hexahydroxy-5 ⁇ ,8 ⁇ ,9 ⁇ -cholestan-6-one, the structural formula is as follows:
- a new crystal form of brassinolide sterol analogues is crystal form I or crystal form II;
- the X-ray powder diffraction spectrum of the crystal form I represented by Cu-K ⁇ radiation and 2 ⁇ 0.2° diffraction angle is at 6.25°, 8.75°, 9.53°, 12.46°, 13.93°, 16.26°, 17.21, 17.73, 18.69 , 19.81, 20.68, 22.75, 24.13°, 24.99°, 25.77°, 27.07°, 29.66°, 30.78°, 31.82°, 33.11°, 36.14°, 37.69°, 38.90°, 40.37°, 42.53°, 48.76° Has diffraction characteristic peaks;
- the X-ray powder diffraction spectrum of the crystal form II represented by Cu-K ⁇ radiation and 2 ⁇ 0.2° diffraction angle is at 6.59°, 10.74°, 11.94°, 14.62°, 15.31°, 17.56°, 18.42°, 18.80° , 19.75°, 20.76°, 21.88°, 22.57°, 23.87°, 24.81°, 26.45°, 28.09°, 28.71°, 29.65°, 31.39°, 33.46°, 34.40°, 36.83°, 38.11°, 38.72°, 39.76 °, 41.66°, 43.05°, 46.42°, 47.02°, 47.45° showed diffraction characteristic peaks.
- the infrared spectrum of the crystal form I has wavenumbers of 3425.78cm -1 , 2961.01cm -1 , 2926.81cm -1 , 1696.67cm -1 , 1633.37cm -1 , 1383.39cm -1 , 1064.12cm -1 , 950.79cm -1 , 524.36 There are characteristic peaks at cm -1 .
- the infrared spectrum of the crystal form II is 3431.58cm -1 , 2966.56cm -1 , 2931.38cm -1 , 2361.83cm -1 , 1708.24cm -1 , 1634.57cm -1 , 1455.83cm -1 , 1383.93cm -1 , 1068.20 There are characteristic peaks at cm -1 and 550.62cm -1 .
- a method for preparing a new crystal form of brassinolide sterol analogs comprises the following steps: 1) extracting the crude extract of natural brassinolide analogs from rapeseed pollen; 2) weighing 10- 20 parts of crude extracts of natural brassinolide analogues were dissolved in 20-30 times methanol reagent, and heated to 50-80°C to promote dissolution, to make it completely dissolved, filtered into a test tube while hot, and sealed with a parafilm The hole is cooled and left to stand for volatilization, and the precipitated massive white crystal is the new crystal form I of the brassinosterol analogue;
- the preparation method of crystal form II comprises the following steps: 1) extracting the crude extract of natural brassinolide analogs from rapeseed pollen; 2) weighing 10 to 20 parts of the crude extracts of natural brassinolide analogs and dissolving them in 75-85 times the toluene reagent, and heated to 50-80°C to promote dissolution, and make it completely dissolved, filtered into a test tube while hot, sealed with a sealing film, pierced the hole, cooled and left to volatilize, and precipitated massive granular white crystals It is the new crystal form II of the brassinosteroid sterol analogue.
- the present invention provides a method for preparing a new crystal form of brassinolide sterol analogues.
- the preparation method of the crude extract is the same as the "Application of Natural Brassinolide Lactone Analogues" No. 201210026285.7, including the following steps: 1) using 80 to 100 % (V/V) ethanol aqueous solution to extract the broken rapeseed pollen, retain the filtrate after solid-liquid separation (optionally wherein the filtrate is further concentrated), and obtain the alcohol-soluble extract; 2) mix the alcohol-soluble extract with 0-60% (V/V V) ethanol aqueous solution is mixed, then add ethyl acetate to extract, keep ethyl acetate layer and add esterase to carry out incomplete reaction, then dry, obtain ester-soluble extract; 3) ester-soluble extract is loaded on silica gel chromatographic column, use The mixed solution of methanol and ethyl acetate is eluted, and the eluate containing natural brassin
- the present invention provides an application of a brassinolide sterol analogue or a new crystal form thereof in the field of agriculture, preferably in promoting plant growth.
- the present invention has the following advantages and beneficial effects:
- a brassinoid sterol analog and its crystal form provided in the embodiment of the present invention have significant biological activity
- the method for preparing a new crystal form of brassinolide sterol analogs provided by the embodiment of the present invention improves the purification method of pollen crude extract, and obtains two new crystal forms with high biological activity through recrystallization, which can be applied to Promotes the growth of plants in the field of agriculture.
- Fig. 1 is the high-resolution mass spectrogram of the brassinolide sterol analog provided by the embodiment of the present invention
- Fig. 2 is the carbon nuclear magnetic spectrum of the new crystal form of the brassinolide sterol analog provided by the embodiment of the present invention
- Fig. 3 is the powder diffraction pattern of the new crystal form I provided by the embodiment of the present invention.
- Fig. 4 provides the powder diffraction pattern of new crystal form II for the embodiment of the present invention
- Fig. 5 is the infrared spectrogram of the new crystal form I provided by the embodiment of the present invention.
- Fig. 6 is the infrared spectrogram of the new crystal form II provided by the embodiment of the present invention.
- Figure 7 is the TG diagram of the new crystal form I provided by the embodiment of the present invention.
- Figure 8 is the TG diagram of the new crystal form II provided by the embodiment of the present invention.
- Figure 9 is a DSC chart of the new crystal form I provided by the embodiment of the present invention.
- Figure 10 is a DSC chart of the new crystal form II provided by the embodiment of the present invention.
- Figure 11 is a solubility curve diagram of the new crystal form I in ethanol provided by the embodiment of the present invention.
- Figure 12 is the solubility curve of the new crystal form II in ethanol provided by the embodiment of the present invention.
- Figure 13 is the solubility curve of the new crystal form I in water provided by the embodiment of the present invention.
- Fig. 14 is a solubility curve of the new crystal form II in water provided by an embodiment of the present invention.
- ester-soluble extract is loaded on a silica gel chromatographic column, eluted with a mixture of methanol and ethyl acetate, and the eluate containing natural brassinolide analogs is collected, then dried to obtain natural brassinolide Analog crude extract;
- ester-soluble extract is loaded on a silica gel chromatographic column, eluted with a mixture of methanol and ethyl acetate, and the eluate containing natural brassinolide analogs is collected, then dried to obtain natural brassinolide Analog crude extract;
- Example 1 The difference from Example 1 is that the recrystallization method is different, specifically as follows: Weigh 15g of brassinolide sterol analogue, dissolve it in 0.5L of methanol solution, add 1L of acetonitrile solvent and stir evenly, and seal the hole with a parafilm and let it stand Volatile, about 20 days, although small crystal particles appear on the test tube wall, but it is not suitable for X-ray test.
- Example 1 The difference from Example 1 is that the recrystallization method is different, as follows: Weigh 5g of brassinolide sterol analogues, dissolve them in 0.5L ethanol solution, filter and let stand for volatilization for a week, the solution turns into a yellow viscous liquid without crystals Precipitate.
- Example 1 The difference from Example 1 is that the recrystallization method is different, specifically as follows: Weigh 10g of brassinolide sterol analogs, dissolve them in 0.3L of methanol solution, add 0.8L of acetonitrile solvent and stir evenly, filter and place in a long test tube Slowly volatilize, no crystals are precipitated, and after the solvent volatilizes completely, a yellow thick liquid substance remains.
- the molecular chemical formula of the brassinosteroid sterol analogs of the present invention is C 27 H 46 O 7 , and the chemical name is (20R,22R)-2 ⁇ ,3 ⁇ ,14 ⁇ -14,20,22,25-hexahydroxy-5 ⁇ , 8 ⁇ , 9 ⁇ -cholestan-6-one, its molecular structure is shown below:
- the XRD diffraction results of the new crystal form I of the present invention as shown in Figure 3, the X-ray powder diffraction spectrum of crystal form I represented by Cu-K ⁇ radiation and 2 ⁇ 0.2° diffraction angle is at 6.25°, 8.75°, 9.53°, 12.46°, 13.93°, 16.26°, 17.21, 17.73, 18.69, 19.81, 20.68, 22.75, 24.13°, 24.99°, 25.77°, 27.07°, 29.66°, 30.78°, 31.82°, 33.11°, 36 .14° , 37.69°, 38.90°, 40.37°, 42.53°, 48.76° showed characteristic diffraction peaks.
- the XRD diffraction results of the new crystal form II of the present invention as shown in Figure 4, the X-ray powder diffraction spectrum of crystal form II represented by Cu-K ⁇ radiation and 2 ⁇ 0.2° diffraction angle is at 6.59°, 10.74°, 11.94° , 14.62°, 15.31°, 17.56°, 18.42°, 18.80°, 19.75°, 20.76°, 21.88°, 22.57°, 23.87°, 24.81°, 26.45°, 28.09°, 28.71°, 29.65°, 31.39°, 33.46 °, 34.40°, 36.83°, 38.11°, 38.72°, 39.76°, 41.66°, 43.05°, 46.42°, 47.02°, 47.45° showed diffraction characteristic peaks.
- thermogravimetric curve shows that the compound of the present invention has good stability from room temperature to 280°C.
- the embodiment of the present invention provides the application of the new crystal form I and the new crystal II in promoting plant growth. Specifically, the experiment of promoting Arabidopsis root growth is taken as an example. The steps are as follows:
- the new crystal form I and the new crystal II of the present invention prepared as a 10 mg/ml mother liquor with absolute ethanol, prepared and used immediately during the experiment).
- the 7-day-old tobacco seedlings were transplanted and planted in the cultivation room, and the experiment was carried out after 2 days of slowing down the seedlings.
- the treatment agent was formulated according to the experimental design, the leaves of the tobacco seedlings were evenly sprayed, and each treatment was repeated 3 times, with 2 plants in each repetition, that is, 6 seedlings in each treatment. Chemicals entering the soil affect the experimental results.
- the RGB AREA_MM parameter value (leaf area/mm 2 ) of tobacco was recorded with a plant phenotype instrument before and 7 days before the medicine, and the leaf area growth rate was calculated to evaluate the growth-promoting effect of the drug.
- the leaf area growth rate calculation formula is as follows:
- the growth rate of leaf area of different treatment groups 7 days after drug treatment is shown in Table 3. From the experimental results, it can be seen that 7 days after drug treatment, the new crystal forms I and II of the present invention showed obvious growth-promoting effects at a concentration of 0.003 ppm.
- the embodiment of the present invention provides the application of the new crystal form I in promoting plant growth, specifically taking the experiment of soaking seeds to promote the germination and growth of corn as an example, the steps are as follows:
- the new crystal form I of the present invention (prepared as a 10mg/ml mother liquor with absolute ethanol, ready for use during experiments).
- test agent prepares the test agent according to the experimental design, select 20 normal plump corn seeds, put them in the agent, soak the seeds at 26°C for 24 hours, then wash the seeds with clean water, put them in the culture box and put them in a constant temperature incubator for germination
- the germination temperature was set to 2 periods: 14h light, 28°C, 10h dark, 25°C, and cultured for 7 days. Each treatment was repeated 3 times.
- 5 ml of clear water was regularly added with a pipette at 9 o'clock every day to keep the culture box moist. After 7 days, the germination rate was counted, the shoot length and root length were measured, and the root vigor and bud vigor were calculated.
- Germination rate germinated number of treated seeds/treated total number of seeds*100% on the 7th day
- Bud vigor index germination rate on the 7th day*the seedling bud length on the 7th day;
- Root vitality index germination rate on the 7th day * root length of the seedlings on the 7th day.
- the new crystal form I of the present invention has an effect of promoting germination on corn compared with the clean water control at a concentration of 0.03 ppm. From the perspective of root and bud vitality index, the new crystal form I of the present invention has the effect of improving the root vitality index and bud vitality index, and the new crystal form I of the present invention at a concentration of 0.03ppm has the best effect, which is obviously better than the control CK.
- the embodiment of the present invention provides the application of the new crystal form II in promoting plant stress resistance.
- the cold resistance experiment of tobacco is taken as an example. The steps are as follows:
- the new crystal form II of the present invention (prepared as a 10 mg/ml mother solution with absolute ethanol, ready for use during experiments).
- the leaves of the tobacco seedlings were evenly sprayed in the morning, and each treatment was repeated 3 times, and each repetition was 2 plants, that is, a total of 6 seedlings for each treatment.
- cold injury (4°C) treatment was performed, and other conditions remained the same as during normal cultivation.
- the chlorophyll fluorescence QY-max parameter value (theoretical maximum photosynthetic capacity) and Fv/Fm (maximum light quantum yield of PSII) were recorded with a plant phenotype instrument before drug treatment, 6h, 24h of low temperature treatment and 24h of recovery at room temperature (25°C). ).
- QY-max represents the theoretical maximum photosynthetic capacity of plants, and the smaller the reduction rate, the better the plant's low temperature resistance.
- Fv/Fm-lss represents the maximum photon yield of PSII, similar to QY-max, the smaller the decrease rate, the better the plant's low temperature resistance. It can be seen from Table 7 that QY-max and Fv/Fm-lss decrease in each treatment after 6 hours of low-temperature treatment, and the decrease rate of QY-max and Fv/Fm-lss of the new crystal form II of the present invention at a concentration of 0.03ppm is significantly lower than that of Water control.
- Table 8 shows the rate of change of QY-max and Fv/Fm-lss between treatments after 24 hours of low-temperature treatment. It can be seen that with the prolongation of low-temperature time, the differences among treatments gradually decrease. Afterwards, each treatment was placed at room temperature (25°C) for recovery. As shown in Figure 9, after 24 hours of recovery, the recovery effect of the new crystal form II at each concentration was better than that of the water control, and the effect was the best when the concentration was 0.03ppm. In summary, the new crystal form II of the present invention has the activity of anti-low temperature.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Pest Control & Pesticides (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (8)
- 一种如权利要求1所述芸苔素甾醇类似物的新晶型,其特征在于,所述新晶型为晶型Ⅰ或者晶型Ⅱ;所述晶型Ⅰ以Cu-Kα辐射、2θ±0.2°衍射角表示的X-射线粉末衍射光谱图在6.25°、8.75°、9.53°、12.46°、13.93°、16.26°、17.21、17.73、18.69、19.81、20.68、22.75、24.13°、24.99°、25.77°、27.07°、29.66°、30.78°、31.82°、33.11°、36.14°、37.69°、38.90°、40.37°、42.53°、48.76°处显示有衍射特征峰;所述晶型Ⅱ以Cu-Kα辐射、2θ±0.2°衍射角表示的X-射线粉末衍射光谱图在6.59°、10.74°、11.94°、14.62°、15.31°、17.56°、18.42°、18.80°、19.75°、20.76°、21.88°、22.57°、23.87°、24.81°、26.45°、28.09°、28.71°、29.65°、31.39°、33.46°、34.40°、36.83°、38.11°、38.72°、39.76°、41.66°、43.05°、46.42°、47.02°、47.45°处显示有衍射特征峰。
- 根据权利要求2所述的芸苔素甾醇类似物新晶型,其特征在于,晶型Ⅰ的红外光谱在波数为3425.78cm -1、2961.01cm -1、2926.81cm -1、1696.67cm -1、1633.37cm -1、1064.12cm -1处有特征峰。
- 根据权利要求2所述的芸苔素甾醇类似物新晶型,其特征在于,晶型Ⅱ的红外光谱在波数为3431.58cm -1、2966.56cm -1、1708.24cm -1、1634.57cm -1、1383.93cm -1、1068.20cm -1处有特征峰。
- 一种如权利要求2-4任一所述的芸苔素甾醇类似物新晶型的制备方法,其特征在于,晶型Ⅰ的制备方法包括如下步骤:1)从油菜花粉中提取天然芸苔素内酯类似物粗提物;2)称量10~20份天然芸苔素内酯类似物粗提物溶解在20~30倍甲醇试剂,并加热促进溶解,使其溶解完全,趁热过滤至试管中,并用封口膜密封扎孔冷却静置挥发,析出的块状白色晶体即为芸苔素甾醇类似物新晶型Ⅰ。
- 根据权利要求5所述的芸苔素甾醇类似物新晶型的制备方法,其特征在于,晶型Ⅱ的制备方法包括如下步骤:1)从油菜花粉中提取天然芸苔素内酯类似物粗提物;2)称量10~20 份天然芸苔素内酯类似物粗提物溶解在75~85倍甲苯试剂,并加热温度促进溶解,使其溶解完全,趁热过滤至试管中,并用封口膜密封扎孔冷却静置挥发,析出的块状颗粒状白色晶体即为芸苔素甾醇类似物新晶型Ⅱ。
- 如权利要求1所述芸苔素甾醇类似物或权利要求2-4任一所述新晶型在农业领域的应用。
- 根据权利要求7所述的芸苔素甾醇类似物或其新晶型在农业领域的应用,其特征在于,在促进植物生长方面的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22909079.0A EP4403564A1 (en) | 2021-12-24 | 2022-03-29 | Novel brassinosteroid analogue, novel crystalline form and preparation method therefor and application thereof |
US18/547,826 US11970515B1 (en) | 2021-12-24 | 2022-03-29 | Crystal form of Brassinosteroid (BR) analogue, and preparation method and use thereof |
CA3234106A CA3234106A1 (en) | 2021-12-24 | 2022-03-29 | Novel brassinosteroid analogue, novel crystalline form and preparation method therefor and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111604062.XA CN114276400B (zh) | 2021-12-24 | 2021-12-24 | 一种芸苔素甾醇类似物的晶型及其制备方法与应用 |
CN202111604062.X | 2021-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023115741A1 true WO2023115741A1 (zh) | 2023-06-29 |
Family
ID=80875418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/083659 WO2023115741A1 (zh) | 2021-12-24 | 2022-03-29 | 一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11970515B1 (zh) |
EP (1) | EP4403564A1 (zh) |
CN (1) | CN114276400B (zh) |
CA (1) | CA3234106A1 (zh) |
WO (1) | WO2023115741A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114276400B (zh) * | 2021-12-24 | 2023-04-21 | 成都新朝阳作物科学股份有限公司 | 一种芸苔素甾醇类似物的晶型及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2434877C1 (ru) * | 2010-03-30 | 2011-11-27 | Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран | Способ получения 7,8-дигидроаналогов экдистероидов |
CN103214546A (zh) * | 2012-01-18 | 2013-07-24 | 成都新朝阳作物科学有限公司 | 天然芸苔素内酯类似物的应用 |
CN103282373A (zh) * | 2010-10-20 | 2013-09-04 | 泰国研究基金会 | 具有植物生长促进活性的脱皮素类似物 |
CN109221132A (zh) * | 2018-09-13 | 2019-01-18 | 江西鑫邦科技有限责任公司 | 一种用于玉米大豆间作的控旺增产药剂组合物 |
CN110839645A (zh) * | 2019-11-28 | 2020-02-28 | 江西鑫邦科技有限责任公司 | 一种增产型植物生长调节剂及其应用 |
CN114276400A (zh) * | 2021-12-24 | 2022-04-05 | 成都新朝阳作物科学股份有限公司 | 一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 |
-
2021
- 2021-12-24 CN CN202111604062.XA patent/CN114276400B/zh active Active
-
2022
- 2022-03-29 EP EP22909079.0A patent/EP4403564A1/en active Pending
- 2022-03-29 WO PCT/CN2022/083659 patent/WO2023115741A1/zh active Application Filing
- 2022-03-29 CA CA3234106A patent/CA3234106A1/en active Pending
- 2022-03-29 US US18/547,826 patent/US11970515B1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2434877C1 (ru) * | 2010-03-30 | 2011-11-27 | Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран | Способ получения 7,8-дигидроаналогов экдистероидов |
CN103282373A (zh) * | 2010-10-20 | 2013-09-04 | 泰国研究基金会 | 具有植物生长促进活性的脱皮素类似物 |
CN103214546A (zh) * | 2012-01-18 | 2013-07-24 | 成都新朝阳作物科学有限公司 | 天然芸苔素内酯类似物的应用 |
CN109221132A (zh) * | 2018-09-13 | 2019-01-18 | 江西鑫邦科技有限责任公司 | 一种用于玉米大豆间作的控旺增产药剂组合物 |
CN110839645A (zh) * | 2019-11-28 | 2020-02-28 | 江西鑫邦科技有限责任公司 | 一种增产型植物生长调节剂及其应用 |
CN114276400A (zh) * | 2021-12-24 | 2022-04-05 | 成都新朝阳作物科学股份有限公司 | 一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
ODINOKOV V. N., AFON’KINA S. R., SHAFIKOV R. V., SAVCHENKO R. G., GALYAUTDINOV I. V., KHALILOV L. M., SHASHKOV A. S.: "7,8-dihydro analogs of ecdysteroids", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, M A I K NAUKA - INTERPERIODICA, RU, vol. 43, no. 6, 1 June 2007 (2007-06-01), RU , pages 825 - 833, XP093074358, ISSN: 1070-4280, DOI: 10.1134/S107042800706005X * |
SUKSAMRARN, APICHART ET AL.: "Stereoselective Catalytic Hydrogenation of Δ7-6-Ketosteroids in the Presence of Sodium Nitrite", TETRAHEDRON, vol. 58, no. 30, 31 December 2002 (2002-12-31), XP004379332, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(02)00580-X * |
THUSSAGUNPANIT JUTIPORN, JUTAMANEE KANAPOL, KAVEETA LILY, CHAI-ARREE WITITH, PANKEAN PORN, HOMVISASEVONGSA SUREEPORN, SUKSAMRARN A: "Comparative Effects of Brassinosteroid and Brassinosteroid Mimic on Improving Photosynthesis, Lipid Peroxidation, and Rice Seed Set under Heat Stress", JOURNAL OF PLANT GROWTH REGULATION., SPRINGER VERLAG, NEW YORK, NY., US, vol. 34, no. 2, 1 June 2015 (2015-06-01), US , pages 320 - 331, XP093074354, ISSN: 0721-7595, DOI: 10.1007/s00344-014-9467-4 * |
Also Published As
Publication number | Publication date |
---|---|
CN114276400B (zh) | 2023-04-21 |
US11970515B1 (en) | 2024-04-30 |
CA3234106A1 (en) | 2023-06-29 |
CN114276400A (zh) | 2022-04-05 |
US20240158434A1 (en) | 2024-05-16 |
EP4403564A1 (en) | 2024-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hashimoto et al. | Batatasins: New dormancy-inducing substances of yam bulbils | |
WO2023115741A1 (zh) | 一种新的芸苔素甾醇类似物、新晶型及其制备方法与应用 | |
WO2023115742A1 (zh) | 一种芸苔素甾醇类似物、新晶型、制备方法及应用 | |
CN107903260B (zh) | 一种吲哚并二氢吡啶酮化合物及其晶型和制备方法 | |
CN113105285B (zh) | 一种用于粳不籼恢杂交水稻制种的母本花时调节剂及调节花时的方法 | |
US20140309439A1 (en) | Method for extracting anthocyanin derivatives from a plant source | |
CN105111164A (zh) | 精茚虫威的晶型 | |
Templeman et al. | The differential effect of synthetic plant growth substances and other compounds upon plant species I. Seed germination and early growth responses to α-naphthylacetic acid and compounds of the general formula arylOCH2COO R | |
CN107690880A (zh) | 促进罗汉果种子萌发的方法 | |
JPS6158441B2 (zh) | ||
CN106478636A (zh) | 替格瑞洛晶型及制备方法 | |
CN107857779A (zh) | 一种制备高纯度磷酸左奥硝唑酯二钠的方法 | |
CN106717843A (zh) | 一种小麦单倍体胚生试管苗的培养方法 | |
CN104447671B (zh) | 雏菊叶龙胆酮单晶及其制备方法与应用 | |
JP5028600B2 (ja) | タデを用いたルテインの調製方法 | |
CN110687242B (zh) | Neo-克罗烷型二萜类化合物对黑麦草的植物毒活性测试方法 | |
CN115385975B (zh) | 一种天然芸苔素类似物hobr的制备方法 | |
RU2798883C1 (ru) | Применение 6-гидрокси-2,2,4-триметил-1,2-дигидрохинолина в качестве стимулятора роста и всхожести семян сахарной свеклы | |
CN109362735B (zh) | pencolide在制备植物生长调节剂或诱导剂中的应用 | |
RU2196772C1 (ru) | 6-МЕТИЛ-8-МЕТОКСИМЕТИЛ-3-ФЕНИЛИЗОКСАЗОЛО[3',4':4,5]ТИЕНО-[2,3-b]ПИРИДИН, ПРОЯВЛЯЮЩИЙ РОСТОРЕГУЛИРУЮЩУЮ И АНТИСТРЕССОВУЮ АКТИВНОСТЬ | |
Akhtar | Temporal regulation of somatic embryogenesis in guava (Psidium guajava L.) | |
WO2019228260A1 (zh) | 一种天维菌素b的晶型及其制备方法和用途 | |
RU2195457C1 (ru) | Замещенные 4,4-дифенил-1,2-дигидро-4н-3,1-бензоксазины, проявляющие росторегулирующую и антистрессовую активность | |
CN117430655A (zh) | 一种丙酰芸苔素内酯的新晶型、及其制备方法和应用 | |
CN117886737A (zh) | 螺环特胺酸骨架化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22909079 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18547826 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023017902 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023017902 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230904 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3234106 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 22909079.0 Country of ref document: EP Ref document number: 2022909079 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022909079 Country of ref document: EP Effective date: 20240416 |